SRR12202437
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.390
- ALLOGRAFT_REJECTION+0.370
- COMPLEMENT+0.370
- INTERFERON_GAMMA_RESPONSE+0.370
- PROTEIN_SECRETION+0.370
- TNFA_SIGNALING_VIA_NFKB+0.370
- INFLAMMATORY_RESPONSE+0.350
- ANDROGEN_RESPONSE+0.340
- HYPOXIA+0.320
- KRAS_SIGNALING_UP+0.280
Top 10 suppressed
- MYC_TARGETS_V2-0.300
- MYOGENESIS-0.230
- FATTY_ACID_METABOLISM-0.220
- E2F_TARGETS-0.210
- BILE_ACID_METABOLISM-0.190
- CHOLESTEROL_HOMEOSTASIS-0.170
- DNA_REPAIR-0.170
- XENOBIOTIC_METABOLISM-0.160
- KRAS_SIGNALING_DN-0.150
- WNT_BETA_CATENIN_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG464 | — | — | 0.875 |
| 2 | BS_3MYEMXPQ | Med | Medulloblastoma | 0.843 |
| 3 | SJEPD030232_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.833 |
| 4 | SRR35579823 | — | D | 0.831 |
| 5 | 53933_S131 | — | cohortA1 | 0.830 |
| 6 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.825 |
| 7 | SRR35579815 | — | C | 0.821 |
| 8 | MNG1175 | — | — | 0.820 |
| 9 | MNG215 | — | — | 0.819 |
| 10 | ERR2208956 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |